Is pharmacogenetic-guided treatment cost-effective? No one size fits all!
A recently published article by M. Verbelen and colleagues in The Pharmacogenomics Journal is called, “Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?” As Betteridge’s law of headlines states, any headline that ends in a question mark can be answered by the word No. Regrettably, although that article presents useful information, it ends up by Read More >Posted on by 2 Comments
Evidence Matters in Genomic Medicine- Round 4: Where are we with Pharmacogenomic Tests?
Previously, CDC’s Office of Public Health Genomics announced a list of health-related genomic tests and applications, stratified into three tiers according to the availability of scientific evidence and evidence-based recommendations and systematic reviews. The list is intended to promote information exchange and dialogue among researchers, providers, policy makers, and the public. Initially the table relied Read More >Posted on by Leave a comment
Medications for the Masses? Pharmacogenomics is an Important Public Health Issue
Adverse drug events are a serious public health problem. Consider the following facts: an estimated 82% of American adults take at least one medication and 29% take five or more; 700,000 emergency department visits and 120,000 hospitalizations are due to adverse drug events annually; $3.5 billion is spent on extra medical costs of adverse drug Read More >Posted on by 3 Comments